EL

SEC source: 0001001250-21-000047 · edgar.xml · derivative · entry 1

Hyman Jennifer · CIK 0001737388 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,310.39

Underlying: Class A Common Stock · 2.39 shares

Expires not disclosed

F1 · derivative.exercise_price: Not applicable.

F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units.

F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

SEC source: 0001001250-21-000045 · edgar.xml · derivative · entry 2

FRIBOURG PAUL J · CIK 0001070938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,410.31

Underlying: Class A Common Stock · 61.04 shares

Expires not disclosed

F1 · derivative.exercise_price: Not applicable.

F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units.

F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

SEC source: 0001001250-21-000045 · edgar.xml · derivative · entry 1

FRIBOURG PAUL J · CIK 0001070938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,683.87

Underlying: Class A Common Stock · 19.52 shares

Expires not disclosed

F1 · derivative.exercise_price: Not applicable.

F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units.

F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

SEC source: 0001001250-21-000046 · edgar.xml · derivative · entry 2

Hockaday Irvine O Jr · CIK 0001113487 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,498.36

Underlying: Class A Common Stock · 145.25 shares

Expires not disclosed

F1 · derivative.exercise_price: Not applicable.

F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units.

F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company.

F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company.

SEC source: 0001001250-21-000046 · edgar.xml · derivative · entry 1

Hockaday Irvine O Jr · CIK 0001113487 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,815.06

Underlying: Class A Common Stock · 41.68 shares

Expires not disclosed

F1 · derivative.exercise_price: Not applicable.

F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units.

F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company.

F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the company.

SEC source: 0001001250-21-000043 · edgar.xml · derivative · entry 1

BRAVO ROSE MARIE · CIK 0001184314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,503.16

Underlying: Class A Common Stock · 28.32 shares

Expires not disclosed

F1 · derivative.exercise_price: Not applicable.

F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units.

F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

SEC source: 0001001250-21-000044 · edgar.xml · derivative · entry 1

Christianson Wei Sun · CIK 0001514187 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,070.22

Underlying: Class A Common Stock · 16.57 shares

Expires not disclosed

F1 · derivative.exercise_price: Not applicable.

F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units.

F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

SEC source: 0001001250-21-000042 · edgar.xml · derivative · entry 1

BARSHEFSKY CHARLENE · CIK 0001145766 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,145.77

Underlying: Class A Common Stock · 34.98 shares

Expires not disclosed

F1 · derivative.exercise_price: Not applicable.

F2 · kind: Represents reinvestment of dividend equivalents on outstanding stock units.

F3 · derivative.exercise_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

F3 · derivative.expiration_date: The Stock Units will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

SEC source: 0001001250-21-000041 · edgar.xml · derivative · entry 3

TRAVIS TRACEY THOMAS · CIK 0001258930 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,924

Underlying: Class A Common Stock · 22,924 shares

Expires 2024-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 15,282 shares exercisable from and after January 1, 2016; 15,283 shares exercisable from and after January 1, 2017; and 15,283 shares exercisable from and after January 1, 2018.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 15,282 shares exercisable from and after January 1, 2016; 15,283 shares exercisable from and after January 1, 2017; and 15,283 shares exercisable from and after January 1, 2018.

SEC source: 0001001250-21-000041 · edgar.xml · nonDerivative · entry 2

TRAVIS TRACEY THOMAS · CIK 0001258930 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,339

F2 · kind: The sales of the shares of Class A Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1(c) entered into on March 2, 2021.

SEC source: 0001001250-21-000041 · edgar.xml · nonDerivative · entry 1

TRAVIS TRACEY THOMAS · CIK 0001258930 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,263

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 15,282 shares exercisable from and after January 1, 2016; 15,283 shares exercisable from and after January 1, 2017; and 15,283 shares exercisable from and after January 1, 2018.

SEC source: 0001001250-21-000040 · edgar.xml · derivative · entry 3

LAL FAMILY PARTNERS LP · CIK 0001008092 · 10% owner

LAL FAMILY CORP · CIK 0001008093 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,437,628

Underlying: Class A Common Stock · 2,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock may be converted immediately on a one-for-one basis by the holder and are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in the Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F1 · kind: LAL Family Partners L.P. ("LALFP") converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F5 · price: Not applicable.

F4 · derivative.exercise_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock may be converted immediately on a one-for-one basis by the holder and are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in the Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F4 · derivative.expiration_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock may be converted immediately on a one-for-one basis by the holder and are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in the Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F2 · ownership.direct: Owned directly by LALFP. The sole general partner of LALFP is LAL Family Corporation ("LALFC"). LALFC indirectly beneficially owns all shares of Class A Common Stock owned by LALFP, to the extent of its pecuniary interest.

SEC source: 0001001250-21-000040 · edgar.xml · nonDerivative · entry 2

LAL FAMILY PARTNERS LP · CIK 0001008092 · 10% owner

LAL FAMILY CORP · CIK 0001008093 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · kind: Sold by by LALFP.

F2 · ownership.direct: Owned directly by LALFP. The sole general partner of LALFP is LAL Family Corporation ("LALFC"). LALFC indirectly beneficially owns all shares of Class A Common Stock owned by LALFP, to the extent of its pecuniary interest.

SEC source: 0001001250-21-000040 · edgar.xml · nonDerivative · entry 1

LAL FAMILY PARTNERS LP · CIK 0001008092 · 10% owner

LAL FAMILY CORP · CIK 0001008093 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: LAL Family Partners L.P. ("LALFP") converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F1 · price: LAL Family Partners L.P. ("LALFP") converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F2 · ownership.direct: Owned directly by LALFP. The sole general partner of LALFP is LAL Family Corporation ("LALFC"). LALFC indirectly beneficially owns all shares of Class A Common Stock owned by LALFP, to the extent of its pecuniary interest.

SEC source: 0001001250-21-000039 · edgar.xml · nonDerivative · entry 7

BRAVO ROSE MARIE · CIK 0001184314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F8 · price: Sales prices range from $292.51 to $293.23 per share, inclusive.

SEC source: 0001001250-21-000039 · edgar.xml · nonDerivative · entry 6

BRAVO ROSE MARIE · CIK 0001184314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,088

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F7 · price: Sales prices range from $291.38 to $292.11 per share, inclusive.

SEC source: 0001001250-21-000039 · edgar.xml · nonDerivative · entry 5

BRAVO ROSE MARIE · CIK 0001184314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F6 · price: Sales prices range from $290.36 to $291.13 per share, inclusive.

SEC source: 0001001250-21-000039 · edgar.xml · nonDerivative · entry 4

BRAVO ROSE MARIE · CIK 0001184314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,700

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F5 · price: Sales prices range from $289.27 to $290.17 per share, inclusive.

SEC source: 0001001250-21-000039 · edgar.xml · nonDerivative · entry 3

BRAVO ROSE MARIE · CIK 0001184314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,200

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $287.90 to $288.16 per share, inclusive.

SEC source: 0001001250-21-000039 · edgar.xml · nonDerivative · entry 2

BRAVO ROSE MARIE · CIK 0001184314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,400

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $286.76 to $287.53 per share, inclusive.

SEC source: 0001001250-21-000039 · edgar.xml · nonDerivative · entry 1

BRAVO ROSE MARIE · CIK 0001184314 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,100

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F2 · price: Sales prices range from $285.74 to $286.52 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 8

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,371

F4 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F9 · price: Sales prices range from $292.94 to $293.58 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 7

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,273

F4 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F8 · price: Sales prices range from $291.94 to $292.93 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 6

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,794

F4 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F7 · price: Sales prices range from $290.94 to $291.93 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 5

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,799

F4 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F6 · price: Sales prices range from $289.94 to $290.93 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 4

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,200

F4 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F5 · price: Sales prices range from $288.93 to $289.91 per share, inclusive.

SEC source: 0001001250-21-000036 · edgar.xml · nonDerivative · entry 5

LAUDER RONALD S FOUNDATION · CIK 0001008089 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,971

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F2 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F6 · price: Sales prices range from $292.56 to $293.38 per share, inclusive.

SEC source: 0001001250-21-000036 · edgar.xml · nonDerivative · entry 4

LAUDER RONALD S FOUNDATION · CIK 0001008089 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,353

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F2 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F5 · price: Sales prices range from $291.55 to $292.52 per share, inclusive.

SEC source: 0001001250-21-000036 · edgar.xml · nonDerivative · entry 3

LAUDER RONALD S FOUNDATION · CIK 0001008089 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,853

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F2 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $290.53 to $291.51 per share, inclusive.

SEC source: 0001001250-21-000036 · edgar.xml · nonDerivative · entry 2

LAUDER RONALD S FOUNDATION · CIK 0001008089 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,527

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F2 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $289.53 to $290.44 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · derivative · entry 10

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,168,846

Underlying: Class A Common Stock · 406,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F1 · kind: Ronald S. Lauder ("RSL") converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F3 · price: Not applicable.

F2 · derivative.exercise_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F2 · derivative.expiration_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 3

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 360,000

F3 · price: Not applicable.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 370,000

F3 · price: Not applicable.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 406,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Ronald S. Lauder ("RSL") converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F2 · price: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001001250-21-000036 · edgar.xml · nonDerivative · entry 1

LAUDER RONALD S FOUNDATION · CIK 0001008089 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,971

F1 · price: Not applicable.

SEC source: 0001001250-21-000035 · edgar.xml · derivative · entry 1

STERNLICHT BARRY S · CIK 0001034657 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,853.78

Underlying: Class A Common Stock · 93.25 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Stock Unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1).

F2 · kind: Represents grant of Stock Units in lieu of cash for quarterly board and committee member retainers.

F3 · derivative.exercise_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

F3 · derivative.expiration_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

SEC source: 0001001250-21-000033 · edgar.xml · derivative · entry 1

FORESTER LYNN · CIK 0001050985 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,538.35

Underlying: Class A Common Stock · 93.25 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Stock Unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1).

F2 · kind: Represents grant of Stock Units in lieu of cash for quarterly board and committee member retainers.

F3 · derivative.exercise_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

F3 · derivative.expiration_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

SEC source: 0001001250-21-000032 · edgar.xml · derivative · entry 1

Hockaday Irvine O Jr · CIK 0001113487 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,353.11

Underlying: Class A Common Stock · 132.1 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Stock Unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1).

F2 · kind: Represents grant of Stock Units in lieu of cash for quarterly presiding director, board, committee chair, and committee member retainers.

F3 · derivative.exercise_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

F3 · derivative.expiration_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

SEC source: 0001001250-21-000031 · edgar.xml · derivative · entry 1

FRIBOURG PAUL J · CIK 0001070938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,349.27

Underlying: Class A Common Stock · 103.61 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Stock Unit (cash payout) is convertible into cash equal to the value of one share of Class A Common Stock (i.e. 1:1).

F2 · kind: Represents grant of Stock Units in lieu of cash for quarterly board and committee member retainers.

F3 · derivative.exercise_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

F3 · derivative.expiration_date: The Stock Units (cash payout) will be paid out the first business day of the calendar year following the last date of the Reporting Person's service as a director of the Company.

SEC source: 0001001250-21-000038 · edgar.xml · nonDerivative · entry 3

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $291.51 to $292.42 per share, inclusive.

SEC source: 0001001250-21-000038 · edgar.xml · nonDerivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,874

F1 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $290.49 to $291.48 per share, inclusive.

SEC source: 0001001250-21-000038 · edgar.xml · nonDerivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,001

F1 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F2 · price: Sales prices range from $289.45 to $290.31 per share, inclusive.

SEC source: 0001001250-21-000029 · edgar.xml · derivative · entry 8

PROUVE CEDRIC · CIK 0001206140 · Group President, International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,337

Underlying: Class A Common Stock · 10,668 shares

Expires 2029-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 10,668 shares exercisable from and after January 1, 2021; 10,668 shares exercisable from and after January 1, 2022 and 10,668 shares exercisable from and after January 1, 2023.

F8 · price: Not Applicable

F2 · derivative.exercise_date: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 10,668 shares exercisable from and after January 1, 2021; 10,668 shares exercisable from and after January 1, 2022 and 10,668 shares exercisable from and after January 1, 2023.

SEC source: 0001001250-21-000029 · edgar.xml · derivative · entry 7

PROUVE CEDRIC · CIK 0001206140 · Group President, International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,081

Underlying: Class A Common Stock · 4,085 shares

Expires 2028-09-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 13,080 shares exercisable from and after January 1, 2020; 13,081 shares exercisable from and after January 1, 2021 and 13,081 shares exercisable from and after January 1, 2022.

F8 · price: Not Applicable

F1 · derivative.exercise_date: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 13,080 shares exercisable from and after January 1, 2020; 13,081 shares exercisable from and after January 1, 2021 and 13,081 shares exercisable from and after January 1, 2022.

SEC source: 0001001250-21-000029 · edgar.xml · nonDerivative · entry 6

PROUVE CEDRIC · CIK 0001206140 · Group President, International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,519

F3 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F7 · price: Sales prices range from $295.18 to $295.43 per share, inclusive.

SEC source: 0001001250-21-000029 · edgar.xml · nonDerivative · entry 5

PROUVE CEDRIC · CIK 0001206140 · Group President, International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,523

F3 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F6 · price: Sales prices range from $294.26 to $295.15 per share, inclusive.

SEC source: 0001001250-21-000029 · edgar.xml · nonDerivative · entry 4

PROUVE CEDRIC · CIK 0001206140 · Group President, International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,490

F3 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F5 · price: Sales prices range from $293.18 to $294.17 per share, inclusive.

SEC source: 0001001250-21-000029 · edgar.xml · nonDerivative · entry 3

PROUVE CEDRIC · CIK 0001206140 · Group President, International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 248,797

F3 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $292.18 to $293.11 per share, inclusive.

SEC source: 0001001250-21-000029 · edgar.xml · nonDerivative · entry 2

PROUVE CEDRIC · CIK 0001206140 · Group President, International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 10,668 shares exercisable from and after January 1, 2021; 10,668 shares exercisable from and after January 1, 2022 and 10,668 shares exercisable from and after January 1, 2023.

F2 · price: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 10,668 shares exercisable from and after January 1, 2021; 10,668 shares exercisable from and after January 1, 2022 and 10,668 shares exercisable from and after January 1, 2023.

SEC source: 0001001250-21-000029 · edgar.xml · nonDerivative · entry 1

PROUVE CEDRIC · CIK 0001206140 · Group President, International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 13,080 shares exercisable from and after January 1, 2020; 13,081 shares exercisable from and after January 1, 2021 and 13,081 shares exercisable from and after January 1, 2022.

F1 · price: Stock Options granted pursuant to Fiscal 2002 Share Incentive Plan in respect of 13,080 shares exercisable from and after January 1, 2020; 13,081 shares exercisable from and after January 1, 2021 and 13,081 shares exercisable from and after January 1, 2022.